4D Molecular Therapeutics enrolls first patients in Phase 3 4SIGHT trial of 4D-150 for diabetic macular edema
FDMT•4D Molecular Therapeutics enrolled the first patients in its global Phase 3 4SIGHT trial of 4D-150 for treatment-naïve diabetic macular edema. Updated two-year SPECTRA results showed durable vision and anatomical improvements with reduced need for frequent injections.
1. Trial advances to Phase 3
4D Molecular Therapeutics enrolled the first patients in 4SIGHT, a global Phase 3 trial of 4D-150 in treatment-naïve diabetic macular edema. The program advances 4D-150 into a second large retinal market beyond wet AMD; regulators have discussed a potential filing strategy relying on this study alongside prior DME and wet AMD data.
2. Updated SPECTRA results
Updated two-year SPECTRA results were presented, supporting durable vision and anatomical improvements with reduced need for frequent injections.
